Glenmark Pharmaceuticals Limited (IN:GLENMARK)
:GLENMARK
GLENMARK Stock Chart & Stats
₹2065.95
-₹29.45(-1.81%)
At close: 4:00 PM EST
₹2065.95
-₹29.45(-1.81%)
Day’s Range― - ―
52-Week Range₹1,336.95 - ₹2,297.20
Previous CloseN/A
Volume301.32K
Average Volume (3M)28.97K
Market Cap
₹596.39B
Enterprise Value₹582.37B
Total Cash (Recent Filing)₹29.58B
Total Debt (Recent Filing)₹12.24B
Price to Earnings (P/E)35.6
Beta0.57
Next Earnings
May 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.24%
Share Statistics
EPS (TTM)14.28
Shares Outstanding282,200,800
10 Day Avg. Volume44,119
30 Day Avg. Volume28,971
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)4.81
Price to Sales (P/S)3.19
P/FCF Ratio-27.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,940.00Price Target Upside-6.10% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)81.87
Revenue Forecast (FY)₹158.19B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained high revenue growth (25%+ reported) signals expanding product adoption and market penetration across segments. Over 2-6 months this supports scale benefits, pricing power in some therapies, and a larger base to absorb costs, improving long-run operating leverage.
Diversified Business ModelGlenmark’s multi-channel model—branded India portfolio, international generics, manufacturing and out-licensing—reduces dependency on any single market or product. Structural diversity supports steadier revenue streams, mitigates single-market regulatory exposure, and aids long-term resilience.
Stable Core MarginsStable EBIT/EBITDA margins point to consistent operational efficiency in manufacturing and commercialization. Even with net income swings, durable core margins imply the business can sustain operating profitability, fund reinvestment, and defend margins versus peers over months.
Bears Say
High LeverageElevated debt relative to equity increases interest and refinancing risk, constraining financial flexibility. Over the medium term this can magnify stress during revenue or cash shortfalls, limit strategic investments, and raise cost of capital for product development or acquisitions.
Weak Cash GenerationNegative operating and free cash flow indicate the company is not internally funding capex and operations, creating persistent liquidity pressure. Structurally, this forces reliance on external financing or asset sales, increasing vulnerability to funding-cycle disruption and higher financing costs.
Profitability VolatilityVolatile net income and margins undermine earnings predictability, complicating planning for R&D, marketing, and debt servicing. Over several months this variability can weaken stakeholder confidence, complicate credit negotiations, and limit ability to commit to long-term strategic investments.
Glenmark Pharmaceuticals Limited News
GLENMARK FAQ
What was Glenmark Pharmaceuticals Limited’s price range in the past 12 months?
Glenmark Pharmaceuticals Limited lowest stock price was ₹1336.95 and its highest was ₹2297.20 in the past 12 months.
What is Glenmark Pharmaceuticals Limited’s market cap?
Glenmark Pharmaceuticals Limited’s market cap is ₹596.39B.
When is Glenmark Pharmaceuticals Limited’s upcoming earnings report date?
Glenmark Pharmaceuticals Limited’s upcoming earnings report date is May 22, 2026 which is in 43 days.
How were Glenmark Pharmaceuticals Limited’s earnings last quarter?
Glenmark Pharmaceuticals Limited released its earnings results on Jan 30, 2026. The company reported ₹14.28 earnings per share for the quarter, missing the consensus estimate of ₹18.7 by -₹4.42.
Is Glenmark Pharmaceuticals Limited overvalued?
According to Wall Street analysts Glenmark Pharmaceuticals Limited’s price is currently Overvalued.
Does Glenmark Pharmaceuticals Limited pay dividends?
Glenmark Pharmaceuticals Limited pays a Monthly dividend of ₹2.5 which represents an annual dividend yield of 0.24%. See more information on Glenmark Pharmaceuticals Limited dividends here
What is Glenmark Pharmaceuticals Limited’s EPS estimate?
Glenmark Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Glenmark Pharmaceuticals Limited have?
Glenmark Pharmaceuticals Limited has 282,200,800 shares outstanding.
What happened to Glenmark Pharmaceuticals Limited’s price movement after its last earnings report?
Glenmark Pharmaceuticals Limited reported an EPS of ₹14.28 in its last earnings report, missing expectations of ₹18.7. Following the earnings report the stock price went up 1.518%.
Which hedge fund is a major shareholder of Glenmark Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:GLENMARK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
GLENMARK Stock 12 Month Forecast
Average Price Target
₹1,940.00
▼(-6.10% Downside)
Technical Analysis
Alkem Laboratories Ltd.
―
Aurobindo Pharma Ltd
―
Biocon Limited
―
GlaxoSmithKline Pharmaceuticals Limited
―
Lupin Limited
―